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Abstract  
Insights distilled from integrating multiple big-data or ‘omic’ datasets have revealed functional hierarchies of 
molecular networks driving tumorigenesis and modifiers of treatment response. Identifying these novel key 
regulatory and dysregulated elements is now informing personalised medicine. 
 
Crucially, while there are many advantages to this approach, there are several key considerations to address. 
Here, we examine how this big-data led approach is impacting many diverse areas of cancer research, through 
review of the key presentations given at the Irish Association for Cancer Research meeting and importantly how 
the results may be applied to positively affect patient outcomes. 
 
  
Introduction 
Recent advances in understanding tumour development and treatment response has evolved to use a combined 
analysis integrating multiple parallel ‘omic’ datasets (genomics, proteomics, transcriptomics, microbiomics) 
generated from each tumour sample, producing functional hierarchies of molecular networks (Aviner et al, 
2015; Franzosa et al, 2015; Kulbe et al, 2016; Yugi et al, 2016). The analysis of these functional hierarchies is 
enhanced by combining many of these networks into larger cohort-based (meta-) networks (targeting diseases 
such as ovarian, colorectal or breast cancer), creating unique insights into the mutational landscapes of cancers, 
the functional consequences in terms of gene expression and dysregulation of the epigenome, such as in 
paediatric neuro-oncology (Northcott et al, 2015). Generating and mapping each patients unique omic profiles 
onto these meta-networks will facilitate truly personalised therapeutics. This synergistic approach has also 
opened exciting new treatment options and facilitated the development of advanced new molecular models of 
disease.  
 
Key elements of producing these molecular networks involve the integration and interpretation of multiple 
large-scale datasets generated from the individual omic systems of each sample (such as the genome, proteome 
and transcriptome). The term “big data” is used interchangeably here to cover three key aspects 1) the size and 
volume of information collected that must be analyzed and shared 2) the numerous types of complex 
information generated and processed and 3) the speed at which this data is generated (Mattmann, 2013). 
Specifically, the immense size of these combined data sets requires new and evolving techniques to allow their 
analysis, revealing highly complex links in parallel processes. Once a network for each sample is created, 
multiple networks are combined to reveal common key processes and molecular elements (Golden et al, 2011). 
Importantly, this approach requires a significant investment in computational infrastructure and bioinformatics 
expertise, both of which are required to effectively manage, exploit and analyse these extraordinarily large 
datasets. Here, we examine the application of this big data approach, through the evaluation of several key 
reports presented at the 2016 Irish Association for Cancer Research meeting. 
 
Improving human tumour models through deconstruction 
A key element to improving our understanding of human cancer is an accurate characterisation of the tumour 
microenvironment (TME). Current approaches to cancer therapeutics integrate induction of tumour cytotoxicity 
with modulation of the TME. A key obstacle to this approach is stratification of the TME to inform these 
treatment strategies and reveal potential novel treatment options (Crusz and Balkwill, 2015). To fully exploit 
this approach requires an in-depth understanding of the influence of genetic mutations driving the tumour and 
how the tumour location impacts the TME. Animal models are essential for research into the TME, but the 
further development of complex 3-D human cell models will complement the animal studies. Novel biophysical 
and biomechanical approaches are required to produce these advanced, complex human 3-D models allowing 
them to support the in vitro 3-D human tumour microenvironment in which malignant, haemopoietic and 
mesenchymal cells will communicate, evolve and grow. 
 
Frances Balkwill (Barts Cancer Institute, Queen Mary University of London) leads the CANBUILD project, 
focusing on a group of high-grade serous ovarian cancers that metastasise to the omentum, which are frequently 
found at disease presentation. The ultimate aim of CANBUILD is to construct this cancerous tissue in vitro 
using autologous cells. This European Research Council and Cancer Research UK funded multi-disciplinary 
project is responding to an urgent need for models that facilitate examination of the interaction between human 
immune cells and malignant cells from the same individual, in an appropriate 3-D biomechanical 
microenvironment.  
 
A key element of their approach is ‘deconstruction’ of the TME. This involves genomic, transcriptomic and 
proteomic profiling of ovarian tumours. Using big data techniques to integrate these profiles facilitates the 
production of a template for ‘reconstruction’ (defining cell types, intra- and extra- cellular signaling pathways, 
genetic influences). This integrated dataset will be used to produce a model that can be refined based on 
additional observations. Eventually it is hoped the model will provide predictions that can be tested in vivo and 
ultimately influence clinical decisions. Using the data generated from the deconstruction stage, the group is 
reconstructing the tumour in silico. This facilitates multivariate analysis of relationships between the molecular 
features, genes and proteins, higher order structures, tissue biomechanics, tissue architecture and cellularity 
(unpublished data). The reconstruction phase is currently testing three bioengineering approaches 
(functionalised PEG hydrogels, peptide amphiphiles and a novel artificial omentum) to reconstruct a complex 
3D TME in vitro (unpublished data).  
 
 
Extracellular tumour signalling  
It is widely appreciated that in addition to cancer cells, solid tumours contain infiltrating host cells and changes 
in the extracellular matrix (Egeblad et al, 2010). These infiltrating cells (including fibroblasts, endothelial cells 
and immune cells) have been demonstrated to fundamentally alter tumour biology, modifying key clinical 
parameters such as disease progression, response to therapy and metastasis (Hanahan and Weinberg, 2011). 
Importantly, it is currently not well understood how these underlying mechanisms facilitate the ability of 
tumour cells to recruit and co-opt these host cells and conversely, how these interactions modulate tumour cell 
function. 
 
Multiple approaches have been used to address how tumour cells interact with local stromal cells including 
imaging, small molecule screening, transcriptional profiling and proteomics analysis using models ranging from 
complex in vivo to reductionist model systems (Hirata et al, 2015; Avgustinova et al, 2016; Locard-Paulet et al, 
2016). A major technical challenge in dissecting cellular signalling between tumour and host cells still remains 
where extracting proteins from solid tumours or multicellular in vitro models typically result in loss of cell-
specific information of the signalling molecules of interest.   
 
To understand cell-specific signalling in a multicellular context Claus Jorgensen’s group (Cancer Research UK 
Manchester Institute, The University of Manchester) have combined stable isotope labelling of individual cell 
populations with proteomics analysis (SILAC) (Locard-Paulet et al, 2016; Jorgensen et al, 2009; Anton et al, 
2014; Tape et al, 2014). Combining the SILAC approach with a global phospho-proteomics analysis and 
informatics analysis of regulated phospho-motifs allows prediction of pathways that are regulated, importantly 
identifying the regulation in a context-dependent manner (Tape et al, 2014; Jorgensen et al., 2009). 
 
Through these data-integrative approaches, they are combining multiple datasets in order to describe how 
signals are processed in a cell-specific manner. The long-term outcome will be to understand how specific 
signals are processed to promote tumour progression and how blocking these signals can enhance therapeutic 
responses. 
 
Virally-induced epigenetic changes induce tumourigenesis  
The power and insights gained by generating and combining omic data was demonstrated by John Greally 
(Albert Einstein School of Medicine, New York), using two examples of virally-induced neoplasia: 
hepatocellular carcinoma (HCC) in patients infected with hepatitis C virus, and cervical epithelial neoplasia in 
women infected with human papilloma virus.  These tumours distinctively allow preneoplastic or early 
neoplastic stages of development of carcinoma to be studied, the cirrhotic and inflamed liver in HCC and the 
cervical intraepithelial neoplasia (CIN) stages preceding cervical carcinoma.  
  
The hypothesis being tested was that epigenetic events create field defects predisposing to later mutational 
events that drive malignant transformation, using virally-induced neoplasia with distinct neoplastic stages of 
development. Using genome-wide DNA methylation patterns, a common theme in both tumour types was 
demonstrated: an early acquisition of DNA methylation that is sustained in later stages of progression, with a 
late event of global loss of DNA methylation coincident with carcinomatous transformation (unpublished data).   
 
Significantly, both cancer types were characterised by a subset of loci acquiring DNA methylation at known 
targets of polycomb repression. An immunohistochemical study revealed that the EZH2 component of 
polycomb is expressed in infected cervical epithelium, with increased expression correlating with neoplasia 
progression (unpublished data).  This work provides insights into the potential mechanisms of each of these 
cancer types, a foundation for the development of predictive biomarkers, and the potential targeting of 
polycomb for pre-neoplastic chemoprevention. 
 
Highlighted in these studies was the need to manage and analyse the data from large numbers of individuals.  
Significantly, these studies also highlighted the need to collect technical metadata (data describing the 
experimental genomic data generation) important for correct data analysis. They found that technical influences 
significantly affected the DNA methylation patterns observed and these needed to be removed before high 
confidence findings could be identified.  
 
Professor Greally described incorporating data from The Cancer Genome Atlas (TCGA), demonstrating the 
value of publically available high-quality reference datasets. Using this integrated data he described how 
epigenetic and transcriptional data can be combined, producing greater insights into the disease process, an 
integration approach that involves significant analytical and computational challenges.  
 
Constructing the cancer specific microbiome 
While there is an established symbiotic interaction between a host and their microbiota, it is only recently that 
clear evidence has emerged demonstrating the presence and role of microbiota in carcinogenesis (Cho and 
Blaser, 2012; Schwabe and Jobin, 2013; Thomas and Jobin, 2015). The use of genomic sequencing to 
understand and map somatic tumour mutations revealed additional non-human sequences present in many 
cancers, which are often filtered out prior to analysis. However, the recognition of bacteria as a key element in 
many human cancers highlighted the need to specifically analyse these non-human sequences. Using high 
throughput sequencing, followed by computational subtraction of human sequences revealed microbial in 
cancer samples. Susan Bullman (The Meyerson group, Department of Medical Oncology, Dana-Farber Cancer 
Institute) highlighted this approach. The development of computational approaches, such as PathSeq (Kostic et 
al, 2011), allowed the isolation of non-human DNA sequences in deep-sequenced human disease tissue 
samples. Subsequently, cancer-associated bacteria (such as Helicobacter pylori) have been described in several 
cancer types (de Martel et al, 2008; Schwabe and Jobin, 2013; Faïs et al, 2016). Recognizing the presence of 
bacteria in tumours has shed light on our understanding of cancer progression and importantly the mechanisms 
affecting how tumours respond to genotoxic therapeutics.  
 
The TCGA has provided an unprecedented opportunity for sequencing-based pathogen discovery in cancer 
through the generation of large-scale sequencing data (up to 11,000 samples for approximately 33 human cancer 
types). Using an inventive computational approach, combined with the TCGA data, the Meyerson group 
profiled microbial signatures across more than 20 tumour types. Analyzing RNAseq and/or WGS data from 
more than 4,000 human tumour samples from TCGA cohorts using PathSeq allowed the identification of 
resident bacteria, viruses, fungi, bacteriophage and archaea within each tumour or normal tissue specimen. This 
led to identification of microbial species enriched in tumour tissue, compared to matched-normal tissue using 
LDA Effect Size analysis (Segata et al, 2011). In addition, correlations between the abundance of specific 
microbes and host gene expression (RNAseq data), protein profiles (RPPA data), mutation signatures (whole 
exome sequencing and WGS), molecular subtypes and other clinicopathological details can be used to further 
characterize the effects of bacteria present in tumours.  
 
This approach identifies bacterial species that are enriched or depleted within human tumours. The application 
of this approach revealed an overabundance of Fusobacterium nucleatum in association with colorectal cancer 
(Kostic et al, 2012).  Further demonstrating the power of this approach, DNA sequencing of cord colitis samples 
revealed previously unknown, non-human, sequences. The assembly of these sequences produced a draft 
bacterial genome with a high degree of homology to the Bradyrhizobium genus of bacteria, with the new strain 
provisionally named Bradyrhizobium enterica. B. enterica nucleotide sequences were subsequently found in 
biopsy specimens from cord colitis patients, but not in healthy control samples (Bhatt et al, 2013). These 
approaches emphasized the importance of determining differences between cancer-associated and non-cancer 
associated bacterial strains. Identifying different genomic features between strains and determining if these 
changes are shared specifically between tumour isolates could potentially reveal “high-risk” strains. 
 
Clearly, evaluating the tumour microbiome as a key component of the tumour microenvironment will provide 
novel insights into how pathogens contribute to tumorigenesis, affect treatment and may ultimately lead to 
novel therapeutic targets. 
 
Modelling led discovery of prognostic biomarkers 
Many simpler biological systems (individual datasets) have classically been studied using statistical methods, 
which fail to account for time-dependent changes in functionality or network topology (arrangement of the 
elements). One systems biology approach to integrate changes in functionally and network topology involves 
the application of ordinary differential equation (ODE), used to describe how quantities change over 
(continuous) time, for data mining. This has allowed systems biology mathematical models to begin revealing 
new disease related insights.  
 
Recent work by the Prehn Group (Centre for Systems Medicine, Royal College of Surgeons in Ireland) has 
implicated deregulation of the apoptosis pathway with chemotherapy resistance. Their ODE based modelling of 
apoptosis signalling has provided prognostic insights and predictive tools for colorectal cancer (CRC). 
 
ODE based mechanistic mathematical models were used to predict upstream apoptosis signalling controlled by 
the BCL-2 family, ultimately regulating mitochondrial permeabilisation (Lindner et al, 2013). The model 
developed by the Prehn group proved to be a potent systems-based prognostic tool for stage III CRC and has 
significant potential as a predictive tool for 5-FU-based chemotherapy in stage II CRC patients. The strength of 
this approach was demonstrated as the model predicted patient mortality independent of pathological TNM 
staging and KRAS mutational status. However, predictions are strongly dependent on the previously described 
Consensus Molecular Subtypes (1 & 3) (Guinney et al, 2015). Current work is exploring the potential of this 
approach, by applying the model as a predictive prognostic tool to stratify the response of CRC patients treated 
with BCL-2 antagonists. 
 
This demonstrates the power of using systems based modelling to assess complex protein-protein network 
interactions, producing clinically relevant prognostic tools. 
 
Concluding remarks 
The 2016 the Irish Association for Cancer Research meeting brought together some of the best international and 
Irish cancer researchers, highlighting the importance of big data led approaches facilitating a more complete 
understanding of each tumour type and helping us understand how tumours are supported within the host. A key 
message delivered was that comprehensively omic profiling human tumours and the surrounding tumour 
microenvironment can reveal mechanisms of tumorogenesis (viral and bacterial), generate prognostic 
biomarkers and identify potential therapeutic targets for personalised treatment.  
 
The studies presented at this meeting highlight the need to capture datasets, generated by omic studies, 
describing the patient or sample. Facilitating big data management is the use of high-powered cloud computing, 
allowing storage, analysis through increased computing power and access (internal and external) of these large 
datasets (or storage in online repositories), relatively cheaply. Clearly, to exploit these combined datasets for 
cancer research requires accurate data management and new informative analysis processes. This will deliver on 
the promise of breakthroughs (fundamental and clinical) provided by in silico based, system wide, approaches 
to cancer analysis. This will allow more precise, individualised targeted therapeutic regimes to be developed 
and will ultimately improve patient outcomes.  
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